Search Results

GammaDelta Therapeutics, a biotechnology company co-founded by researchers from the Francis Crick Institute and King's College London, has announced that it has initiated a First-in-Human Phase I clinical trial in the US, evaluating a unique gamma-delta (γδ) T cell therapy for the treatment of acute myeloid leukaemia.

GammaDelta Therapeutics has received Investigational New Drug approval from the U.S. Food and Drug Administration (FDA) for the Company’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy, GDX012, to be investigated as a treatment for blood cancers. 

Scientists at global biopharmaceutical company MSD and the Crick have started a unique new collaboration to understand the causes of Motor Neurone Disease.

Researchers at the Francis Crick Institute are helping to run the largest clinical study of Long COVID to date.